News
Median overall survival of 17.3 months in Bria-IMT treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback